Form 4: Boston Scientific Director Susan Morano Receives Equity Awards

Boston Scientific Director Susan E. Morano was granted restricted stock awards valued at approximately $287,500 on May 7, 2026, as part of her annual compensation.

Summary

• Director Susan E. Morano received two grants of restricted stock on May 7, 2026.
• The first grant is an annual equity award valued at $215,000, which will vest in full upon the next annual stockholder meeting.
• The second grant is in lieu of 50% of her yearly cash compensation, valued at approximately $72,500, and will also vest in full upon the next annual stockholder meeting.
• These awards represent a total of 5,081 shares of common stock (3,800 + 1,281).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation through equity awards rather than significant financial performance or strategic shifts.

Positives

• Director compensation is being provided through equity awards, aligning management interests with shareholders.
• The equity awards vest upon the next annual meeting, providing a clear performance incentive tied to company governance.
• The total value of equity awards granted to Director Morano is substantial, indicating a commitment to retaining experienced leadership.

Negatives

• The filing does not provide specific details on the company's financial performance or outlook, making it difficult to assess the broader context of these awards.

Risks

• The value of the restricted stock awards is subject to the future market price of Boston Scientific's common stock.
• Vesting is tied to the next annual meeting, meaning any significant corporate governance issues or underperformance leading up to that meeting could impact the realization of these awards.

Future Outlook

The future outlook for the value of these awards is dependent on the company's stock performance leading up to the next annual stockholder meeting.

Management Comments

• The awards are structured to vest in full upon the next annual meeting of stockholders.
• The second award represents 50% of the yearly cash compensation for a non-employee director, with a portion allocated to committee chair retainers.

Industry Context

StockSavvy.ai notes that equity awards for directors are a common practice in the medical technology industry to ensure alignment with shareholder interests and to attract and retain experienced leadership.

Comparison to Industry Standards

• The structure of these awards, with vesting tied to the annual meeting, is a standard practice among publicly traded companies in the healthcare and medical device sectors.
• The total value of the awards ($287,500) is within the typical range for non-employee director compensation at companies of Boston Scientific's size and market capitalization, though specific comparisons would require access to detailed compensation surveys.

Stakeholder Impact

• Shareholders: The equity awards align director compensation with the company's stock performance, potentially benefiting shareholders through increased director focus on value creation.
• Employees: This filing does not directly impact employees.
• Creditors: This filing has no direct impact on creditors.
• Suppliers: This filing has no direct impact on suppliers.
• Customers: This filing has no direct impact on customers.

Next Steps

• The restricted stock awards will vest in full upon the next annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Equity Award, Restricted Stock, Director Compensation, SEC Filing, Beneficial Ownership